An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Eladocagene exuparvovec (Primary)
- Indications Aromatic amino acid decarboxylase deficiency
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors PTC Therapeutics
Most Recent Events
- 30 May 2024 New trial record
- 18 Apr 2024 Results assessing pharmacodynamics of eladocagene exuparvovec and the safety of the SmartFlow magnetic resonance (MR)-compatible ventricular cannula presented at the 76th Annual Meeting of the American Academy of Neurology 2024